Edelris announce today that they have out-licensed to Enyo Pharma the patent they co-own with Inserm, Poxel, CNRS, UCBL and ENS-Lyon on a new treatment to cure Hepatitis B.
Hepatitis B virus (HBV) infection is a major public health problem with more than 350 million people chronically infected worldwide, 20 to 40% of them being at risk of developing chronic liver disease, cirrhosis and hepatocellular carcinoma. Despite the existence of an effective preventive vaccine, the HBV infection is still rampant in many countries, including developed ones, with an estimated 4.5 million new cases of infection per year worldwide. In the frame of the FUI AAP8 founded program NATHEB initiated in 2009 and led by Edelris, with its partners Inserm and Poxel, FXR has been identified as a therapeutic target for HBV and new compounds have been discovered, leading to a strong inhibition of viral HBV DNA and viral antigen production.
"This project demonstrates the ability of Edelris scientists to use their track-proven medchem and molecular modeling expertise to conduct, together with experienced partners at Inserm and Poxel, a successful discovery program. Instrumental to the launch of the project was the contribution of Lyon Biopôle," commented Didier Roche, VP Strategic Innovation of Edelris and former Head of the Natheb project.
"When science and business interests are shared within public-private partnerships, things can move quickly towards valuable results, as has been the case in the Natheb project," added Jean-Yves Ortholand, Edelris' CEO. "We believe Enyo now has the full capability to transform this project into useful therapeutic agents."
Inserm Transfert has been appointed to represent all parties in the patent agreement with Enyo.
Under the license agreement, Edelris is eligible for milestones upon specific development and commercial achievements and would receive royalty payments on sales.
Edelris is a privately-owned research and services company offering original natural product-like collections of screening compounds and innovative fragments for FBDD (Keymical Collections™ and Fragments™), as well as efficient hit/lead optimization capabilities. Since its inception, Edelris has gained many clients worldwide and has successfully developed chemistry programs with major pharmaceutical companies, biotechs and academic groups, either in direct support to their internal discovery efforts or in the framework of collaborative projects.
Contact: Jean-Yves Ortholand